vs

Side-by-side financial comparison of Red Violet, Inc. (RDVT) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $23.4M, roughly 1.5× Red Violet, Inc.). Red Violet, Inc. runs the higher net margin — 12.0% vs -304.2%, a 316.3% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 19.6%). Red Violet, Inc. produced more free cash flow last quarter ($6.6M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 15.6%).

Red Violet, Inc. is a technology firm specializing in advanced data analytics, risk mitigation, and identity verification solutions. It serves clients across law enforcement, financial services, insurance, and corporate compliance sectors, delivering actionable insights from curated public and proprietary data sets to support informed decision-making.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

RDVT vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.5× larger
RXRX
$35.5M
$23.4M
RDVT
Growing faster (revenue YoY)
RXRX
RXRX
+662.2% gap
RXRX
681.7%
19.6%
RDVT
Higher net margin
RDVT
RDVT
316.3% more per $
RDVT
12.0%
-304.2%
RXRX
More free cash flow
RDVT
RDVT
$53.9M more FCF
RDVT
$6.6M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
15.6%
RDVT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RDVT
RDVT
RXRX
RXRX
Revenue
$23.4M
$35.5M
Net Profit
$2.8M
$-108.1M
Gross Margin
59.8%
Operating Margin
6.8%
-304.8%
Net Margin
12.0%
-304.2%
Revenue YoY
19.6%
681.7%
Net Profit YoY
226.2%
39.6%
EPS (diluted)
$0.20
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RDVT
RDVT
RXRX
RXRX
Q4 25
$23.4M
$35.5M
Q3 25
$23.1M
$5.2M
Q2 25
$21.8M
$19.2M
Q1 25
$22.0M
$14.7M
Q4 24
$19.6M
$4.5M
Q3 24
$19.1M
$26.1M
Q2 24
$19.1M
$14.4M
Q1 24
$17.5M
$13.8M
Net Profit
RDVT
RDVT
RXRX
RXRX
Q4 25
$2.8M
$-108.1M
Q3 25
$4.2M
$-162.3M
Q2 25
$2.7M
$-171.9M
Q1 25
$3.4M
$-202.5M
Q4 24
$863.0K
$-178.9M
Q3 24
$1.7M
$-95.8M
Q2 24
$2.6M
$-97.5M
Q1 24
$1.8M
$-91.4M
Gross Margin
RDVT
RDVT
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
RDVT
RDVT
RXRX
RXRX
Q4 25
6.8%
-304.8%
Q3 25
19.8%
-3327.6%
Q2 25
12.6%
-916.8%
Q1 25
19.1%
-1297.9%
Q4 24
1.9%
-4042.4%
Q3 24
13.1%
-377.1%
Q2 24
16.1%
-697.4%
Q1 24
11.3%
-698.4%
Net Margin
RDVT
RDVT
RXRX
RXRX
Q4 25
12.0%
-304.2%
Q3 25
18.3%
-3135.3%
Q2 25
12.3%
-894.2%
Q1 25
15.6%
-1373.3%
Q4 24
4.4%
-3935.5%
Q3 24
9.0%
-367.5%
Q2 24
13.8%
-676.6%
Q1 24
10.2%
-662.4%
EPS (diluted)
RDVT
RDVT
RXRX
RXRX
Q4 25
$0.20
$-0.17
Q3 25
$0.29
$-0.36
Q2 25
$0.18
$-0.41
Q1 25
$0.24
$-0.50
Q4 24
$0.06
$-0.56
Q3 24
$0.12
$-0.34
Q2 24
$0.19
$-0.40
Q1 24
$0.13
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RDVT
RDVT
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$43.6M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$100.9M
$1.1B
Total Assets
$112.0M
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RDVT
RDVT
RXRX
RXRX
Q4 25
$43.6M
$743.3M
Q3 25
$45.4M
$659.8M
Q2 25
$38.8M
$525.1M
Q1 25
$34.6M
$500.5M
Q4 24
$36.5M
$594.4M
Q3 24
$35.7M
$427.6M
Q2 24
$30.9M
$474.3M
Q1 24
$32.1M
$296.3M
Total Debt
RDVT
RDVT
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
RDVT
RDVT
RXRX
RXRX
Q4 25
$100.9M
$1.1B
Q3 25
$101.7M
$1.0B
Q2 25
$96.2M
$919.1M
Q1 25
$91.8M
$933.9M
Q4 24
$86.6M
$1.0B
Q3 24
$91.7M
$524.6M
Q2 24
$88.0M
$584.4M
Q1 24
$83.8M
$401.2M
Total Assets
RDVT
RDVT
RXRX
RXRX
Q4 25
$112.0M
$1.5B
Q3 25
$112.1M
$1.4B
Q2 25
$104.8M
$1.3B
Q1 25
$99.1M
$1.3B
Q4 24
$98.5M
$1.4B
Q3 24
$98.0M
$726.5M
Q2 24
$93.5M
$775.9M
Q1 24
$94.0M
$557.8M
Debt / Equity
RDVT
RDVT
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RDVT
RDVT
RXRX
RXRX
Operating Cash FlowLast quarter
$6.7M
$-46.1M
Free Cash FlowOCF − Capex
$6.6M
$-47.3M
FCF MarginFCF / Revenue
28.1%
-133.1%
Capex IntensityCapex / Revenue
0.5%
3.5%
Cash ConversionOCF / Net Profit
2.38×
TTM Free Cash FlowTrailing 4 quarters
$28.8M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RDVT
RDVT
RXRX
RXRX
Q4 25
$6.7M
$-46.1M
Q3 25
$10.2M
$-117.4M
Q2 25
$7.5M
$-76.4M
Q1 25
$5.0M
$-132.0M
Q4 24
$6.7M
$-115.4M
Q3 24
$7.2M
$-59.2M
Q2 24
$5.7M
$-82.2M
Q1 24
$4.3M
$-102.3M
Free Cash Flow
RDVT
RDVT
RXRX
RXRX
Q4 25
$6.6M
$-47.3M
Q3 25
$10.0M
$-117.6M
Q2 25
$7.3M
$-79.6M
Q1 25
$5.0M
$-133.8M
Q4 24
$6.7M
$-116.7M
Q3 24
$7.2M
$-63.8M
Q2 24
$5.7M
$-83.4M
Q1 24
$4.2M
$-109.0M
FCF Margin
RDVT
RDVT
RXRX
RXRX
Q4 25
28.1%
-133.1%
Q3 25
43.3%
-2272.5%
Q2 25
33.5%
-413.9%
Q1 25
22.5%
-907.4%
Q4 24
34.1%
-2567.7%
Q3 24
37.8%
-244.6%
Q2 24
29.7%
-578.5%
Q1 24
24.2%
-789.9%
Capex Intensity
RDVT
RDVT
RXRX
RXRX
Q4 25
0.5%
3.5%
Q3 25
0.8%
4.7%
Q2 25
0.9%
16.4%
Q1 25
0.2%
12.4%
Q4 24
0.1%
28.6%
Q3 24
0.2%
17.5%
Q2 24
0.3%
8.2%
Q1 24
0.4%
48.2%
Cash Conversion
RDVT
RDVT
RXRX
RXRX
Q4 25
2.38×
Q3 25
2.41×
Q2 25
2.79×
Q1 25
1.45×
Q4 24
7.75×
Q3 24
4.22×
Q2 24
2.17×
Q1 24
2.41×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons